ChAdOx1 COVID-19 vaccine-induced thrombocytopenia syndrome
YH Wang, LY Huang, YL Chen, JS Chan… - … Journal of Medicine, 2021 - academic.oup.com
YH Wang, LY Huang, YL Chen, JS Chan, WF Chiang, CY Lin, MH Chen, HY Shyu, PJ Hsiao
QJM: An International Journal of Medicine, 2021•academic.oup.comDiscussion COVID-19 vaccine-induced TTS can be associated with thrombosis formation in
portal vein, splanchnic vein and hepatic vein. 1–4 TTS is caused by antibodies against PF4,
triggering platelet activation and resulting in thrombosis formation with consumptive
thrombocytopenia. This phenomenon is similar to type II heparin-induced thrombocytopenia.
Medical treatment including IVIG, methylprednisolone, direct oral anticoagulants and even
plasma exchange could be performed in some refractory cases of TTS. 1–4
portal vein, splanchnic vein and hepatic vein. 1–4 TTS is caused by antibodies against PF4,
triggering platelet activation and resulting in thrombosis formation with consumptive
thrombocytopenia. This phenomenon is similar to type II heparin-induced thrombocytopenia.
Medical treatment including IVIG, methylprednisolone, direct oral anticoagulants and even
plasma exchange could be performed in some refractory cases of TTS. 1–4
Discussion
COVID-19 vaccine-induced TTS can be associated with thrombosis formation in portal vein, splanchnic vein and hepatic vein. 1–4 TTS is caused by antibodies against PF4, triggering platelet activation and resulting in thrombosis formation with consumptive thrombocytopenia. This phenomenon is similar to type II heparin-induced thrombocytopenia. Medical treatment including IVIG, methylprednisolone, direct oral anticoagulants and even plasma exchange could be performed in some refractory cases of TTS. 1–4
Oxford University Press